Trial Profile
A Phase Ib/IIa, Open-Label, Dose Finding Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3Kβ Selective Inhibitor (GSK2636771) Administered in Combination With Paclitaxel in Advanced Gastric Adenocarcinoma Having Alterations in PI3K Pathway Genes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs GSK 2636771 (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jan 2022 Results of post-hoc analysis of two studies (NCT02615730 & NCT02951091) presented at the 2022 Gastrointestinal Cancers Symposium.
- 03 Jul 2021 Results of dose-finding study with safety and efficacy analysis of GSK2636771 combined with paclitaxel in patients with advanced gastric cancer (AGC) who progressed from first-line chemotherapy, presented at the 23rd World Congress on Gastrointestinal Cancer.
- 21 Apr 2021 Status changed from active, no longer recruiting to completed.